$NAMS· SEC filing ·

NAMS Announces $8B+ Peak Sales Potential for Obicetrapib, 45% Lp(a) Lowering, $729M Cash Position

NewAmsterdam Pharma Company N.V. Ordinary Shares · PHARMACEUTICAL PREPARATIONS · Now $31.79

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS